DxGen Launches '2 Minutes' COVID-19 Antibody Testing System
|
By LabMedica International staff writers Posted on 19 May 2020 |
|
Image: The newly-developed Epithod 616 analyzer and COVID-19 IgM/IgG test kit from DxGen (Photo courtesy of DxGen Corp.)
A newly-launched '2 minutes' detection system for COVID-19 IgM / IgG antibodies offers reliable testing with several attractive features for medical professionals and has also received CE Mark.
The newly-developed Epithod 616 analyzer and COVID-19 IgM/IgG test kit from DxGen Corp. (South Korea) is the fastest system that not only provides positive (+, ++, +++) or negative (-) results, but also shows the results through a relative numerical value in COI (Cut-Off Index), thus enabling the user to diagnose the levels of IgM and IgG antibodies present and manage their quantitative results more specifically. The Epithod 616 diagnostic system ensures better accuracy and improved sensitivity in analyzing results and eliminates the risk of undesirable misreading which frequently occurs in conventional ‘lateral-flow’ immunoassay tests where the user determines the test results through their own naked eye.
Owing to its unique multi-chromatic reflectometry analyzer and flow-through immunoassay platform, the system can provide test results within two minutes, or more than 100 test results per hour, which significantly improves the total test capacity as compared to the conventional ‘Lateral-flow’ test kit that usually takes at least 10 minutes for each test. Additionally, the Epithod 616 is equipped with user-friendly functions, such as a ‘check-up list’ that enables the user to input patient information in detail, including fever, cough and the number of days since the onset of symptoms.
“It is very important to comprehensively monitor underlying diseases such as diabetes, myocardial infarction and pneumonia together with the COVID-19 disease in order to care the infected patients and to restrain the spread of the outbreak," said Jinwoo Lee, Ph.D., chief executive officer, DxGen Corporation. "Epithod 616 drew great attention from many potential customers who have interest in integrative diagnostics of COVID-19 with HbA1c, Glycated Albumin, CRP, hs-CRP, D-dimer and more. This is very important point to make decisions about the treatment efficacy and convalescence patients."
The newly-developed Epithod 616 analyzer and COVID-19 IgM/IgG test kit from DxGen Corp. (South Korea) is the fastest system that not only provides positive (+, ++, +++) or negative (-) results, but also shows the results through a relative numerical value in COI (Cut-Off Index), thus enabling the user to diagnose the levels of IgM and IgG antibodies present and manage their quantitative results more specifically. The Epithod 616 diagnostic system ensures better accuracy and improved sensitivity in analyzing results and eliminates the risk of undesirable misreading which frequently occurs in conventional ‘lateral-flow’ immunoassay tests where the user determines the test results through their own naked eye.
Owing to its unique multi-chromatic reflectometry analyzer and flow-through immunoassay platform, the system can provide test results within two minutes, or more than 100 test results per hour, which significantly improves the total test capacity as compared to the conventional ‘Lateral-flow’ test kit that usually takes at least 10 minutes for each test. Additionally, the Epithod 616 is equipped with user-friendly functions, such as a ‘check-up list’ that enables the user to input patient information in detail, including fever, cough and the number of days since the onset of symptoms.
“It is very important to comprehensively monitor underlying diseases such as diabetes, myocardial infarction and pneumonia together with the COVID-19 disease in order to care the infected patients and to restrain the spread of the outbreak," said Jinwoo Lee, Ph.D., chief executive officer, DxGen Corporation. "Epithod 616 drew great attention from many potential customers who have interest in integrative diagnostics of COVID-19 with HbA1c, Glycated Albumin, CRP, hs-CRP, D-dimer and more. This is very important point to make decisions about the treatment efficacy and convalescence patients."
Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
New
Amoebiasis Test
ELI.H.A Amoeba
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read more
Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreMolecular Diagnostics
view channel
Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD
Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more
First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more
New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more
Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
The number of individuals affected by osteoarthritis is projected to exceed 1 billion by 2050. The primary risk factor for this common, often painful chronic joint condition is aging, and, like aging itself,... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read more
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Pathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read more
Technology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
